Table 4 Hazard ratios for hepatocellular carcinoma, all-cause mortality, liver-related mortality, non-liver-related mortality, and liver transplant. 483 DAA-exposed versus 76 unexposed patients are compared according to exposure period and virological response status
On treatment N = 483 | SVR N = 391 | No SVR N = 53 | Unknown SVR N = 39 | |||||
|---|---|---|---|---|---|---|---|---|
Univariable HR (95% CI) | Multivariable-adjusted HR (95% CI) | Univariable HR (95% CI) | Multivariable-adjusted HR (95% CI) | Univariable HR (95% CI) | Multivariable-adjusted HR (95% CI) | Univariable HR (95% CI) | Multivariable-adjusted HR (95% CI) | |
Hepatocellular carcinoma | 0.76 (0.45–1.29) | 0.77 (0.43–1.36) | 0.49 (0.28–0.85)* | 0.52 (0.29–0.93)* | 1.53 (0.74–3.18) | 1.16 (0.52–2.60) | 0.50 (0.15–1.71) | 0.50 (0.15–1.73) |
All-cause mortality | 0.35 (0.21–0.57)* | 0.47 (0.25–0.86)* | 0.22 (0.13–0.37)* | 0.29 (0.15–0.54)* | 0.38 (0.13–1.09) | 0.66 (0.19–2.28) | 0.47 (0.17–1.33) | 0.94 (0.28–3.11) |
Liver-related mortality | 0.44 (0.21–0.91)* | 0.61 (0.25–1.47) | 0.29 (0.14–0.62)* | 0.40 (0.17–0.96)* | 0.42 (0.09–1.98) | 0.77 (0.15–4.10) | 0.55 (0.12–2.48) | 0.68 (0.14–3.43) |
Non-liver-related mortality | 0.30 (0.14–0.66)* | 0.26 (0.09–0.76)* | 0.20 (0.09–0.47)* | 0.17 (0.06–0.49)* | 0.24 (0.03–1.73) | 0.18 (0.02–1.28) | 0.57 (0.13–2.50) | 1.38 (0.19–10.10) |
Liver transplant | 0.50 (0.20–1.25) | 0.32 (0.09–1.08) | 0.23 (0.08–0.67)* | 0.17 (0.05–0.54)* | 0.51 (0.06–4.09) | 0.36 (0.07–1.82) | ND | ND |